中文         Site Map |
 
 
 
The Grand Opening of Fosun-Guilin Pharma Afrique
Date: Apr.28.2013
 

2013/1/31, GPAF, subsidiary of Guilin Pharma, has its official opening ceremony in Abidjan, the financial capital of Côte d'Ivoire. Government officials and experts from FDA, National Labs and DPM of Côte d'Ivoire attended the ceremony. GPAF mainly focuses on market exploring of artesumine-based antimalarial drugs, which has also driven its business on generic pharmaceutical products in West Africa region. Mr. Jean-Marc Bouchez will take the position of General Manager and Chief Medical Officer of Guilin Pharma. In the ceremony, Mr. Jean-Marc Bouchez delivered a warm welcome speech, and Ms. Michelle Xiong, representative of Guilin Pharma, congratulated to the establishment of GPAF and extended welcome to all the distinguished guests.

Guilin Pharmaceutical Co., Ltd, a member of Fosun Pharma group, is the first pharmaceutical manufacturer whose oral and parenteral antimalarials pre-qualified by WHO in the world. Its Artesun® (artesunate for injection), WHO pre-qualified in November, 2010, is recommended by WHO <GUIDELINES FOR THE TREATMENT OF MALARIA> as the preferred choice on treating severe malaria in adults and children, and is the only injectable artesunate complying with international quality standard so far.

To expand the international market, Guilin Pharma has set up four branch offices in Myanmar, Nigeria, Kenya and Uganda and one subsidiary company in Ghana, to cover almost all malaria epidemic English-speaking countries. As for the French-speaking countries, which accounts for 40% of the global anti-malarial market, the sales have been suspended because of the strategy shift of our partners.

The establishment of GPAF is no doubt a milestone of exploring overseas market for Guilin Pharma. Côte d'Ivoire is the financial, trade and shipping center of the West Africa, its GDP is 40% of WAEC (West African Economic Community), slightly less than Nigeria. Meanwhile, Côte d'Ivoire has a good infrastructure, sound laws and regulations as well as a great potential market (medical expenses takes up 5.1% of GDP). Due to the location advantages of Côte d'Ivoire, business of GPAF can reach 17 French-speaking countries, and will lay a solid foundation for Guilin Pharma’s business development in African countries.

As a professional pharmaceutical marketing and consulting company, GPAF will provide not only policy affairs such as drugs registration, expert networks and governmental resources web construction, but also terminal market promotion (includes management of business representatives, academic promotion and Phase IV Clinical Monitoring, etc.) . GPAF will promote the brand of Guilin Pharma as a high-tech pharmaceutical enterprise which develops Artesun®, explore the market of artesumine-based FDC (focused on D-ARTEPP® promotion), drive the development of generic production and set up the anti-infective production line. We endeavor to build the brand of Guilin Pharma and develop a long-term growth path.
 

This site is published by Guilin Pharmaceutical (Shanghai) Corporation,        which is solely responsible for its content. All rights reserved.

© Guilin Pharmaceutical (Shanghai) Co., Ltd. 2017.